Nataliya Yeremenko1, Jacqueline E Paramarta, Dominique Baeten. 1. aDepartment of Clinical Immunology and Rheumatology bLaboratory of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.
Abstract
PURPOSE OF REVIEW: Various novel therapies for spondyloarthritis (SpA) are currently under development. In this review, we discuss the scientific rational to target the interleukin (IL)-23/IL-17 axis in SpA and give an overview of the proof-of-concept trials with drugs directed towards this axis. RECENT FINDINGS: Cumulative evidence from genetics (e.g. the strong genetic association with the IL-23 receptor gene), in-vitro models (e.g. the increased IL-23 production upon HLA-B27 misfolding), human expression studies (e.g. the expansion of IL-17 producing innate cells in SpA) and animal models (e.g. the increased IL-17 production in HLA-B27 transgenic rats) strongly supports the involvement of the IL-23/IL-17 axis in the pathogenesis of SpA. Ustekinumab (a monoclonal antibody directed against the common p40 subunit of IL-23 and IL-12), secukinumab, ixekizumab (both monoclonal antibodies directed against IL-17A), and brodalumab a monoclonal antibody against the IL-17RA receptor) have been recently used in proof-of-concept and randomized trials in the ankylosing spondylitis and/or psoriatic arthritis subforms of SpA, with overall very promising clinical efficacy. SUMMARY: The first results for novel drugs blocking key cytokines in the IL-23/IL-17 axis are promising in SpA and more novel compounds are upcoming. This will teach us more on the role of the IL-23/IL-17 axis in the pathophysiology of SpA.
PURPOSE OF REVIEW: Various novel therapies for spondyloarthritis (SpA) are currently under development. In this review, we discuss the scientific rational to target the interleukin (IL)-23/IL-17 axis in SpA and give an overview of the proof-of-concept trials with drugs directed towards this axis. RECENT FINDINGS: Cumulative evidence from genetics (e.g. the strong genetic association with the IL-23 receptor gene), in-vitro models (e.g. the increased IL-23 production upon HLA-B27 misfolding), human expression studies (e.g. the expansion of IL-17 producing innate cells in SpA) and animal models (e.g. the increased IL-17 production in HLA-B27 transgenic rats) strongly supports the involvement of the IL-23/IL-17 axis in the pathogenesis of SpA. Ustekinumab (a monoclonal antibody directed against the common p40 subunit of IL-23 and IL-12), secukinumab, ixekizumab (both monoclonal antibodies directed against IL-17A), and brodalumab a monoclonal antibody against the IL-17RA receptor) have been recently used in proof-of-concept and randomized trials in the ankylosing spondylitis and/or psoriatic arthritis subforms of SpA, with overall very promising clinical efficacy. SUMMARY: The first results for novel drugs blocking key cytokines in the IL-23/IL-17 axis are promising in SpA and more novel compounds are upcoming. This will teach us more on the role of the IL-23/IL-17 axis in the pathophysiology of SpA.
Authors: Eilon Barnea; Dganit Melamed Kadosh; Yael Haimovich; Nimman Satumtira; Martha L Dorris; Mylinh T Nguyen; Robert E Hammer; Tri M Tran; Robert A Colbert; Joel D Taurog; Arie Admon Journal: Mol Cell Proteomics Date: 2017-02-10 Impact factor: 5.911
Authors: Mayya Geha; Maria G Tsokos; Robin E Bosse; Tatyana Sannikova; Yoichiro Iwakura; Jurandir J Dalle Lucca; Rene De Waal Malefyt; George C Tsokos Journal: J Immunol Date: 2017-09-06 Impact factor: 5.422
Authors: Jau-Yi Li; Patrizia D'Amelio; Jerid Robinson; Lindsey D Walker; Chiara Vaccaro; Tao Luo; Abdul Malik Tyagi; Mingcan Yu; Michael Reott; Francesca Sassi; Ilaria Buondonno; Jonathan Adams; M Neale Weitzmann; Giovanni Carlo Isaia; Roberto Pacifici Journal: Cell Metab Date: 2015-10-08 Impact factor: 27.287